Celyad SA CYAD announced that the first patient in the second cohort of its phase I study on NKG2D CAR T-Cell for the treatment of patients with acute myeloid leukemia (AML) and multiple myeloma (MM) has received the infusion.
The study will evaluate safety and feasibility of the candidate, with secondary endpoints including clinical activity. The company expects to present complete data from the phase I study in mid-2016.
Apart from AML and MM, an Investigational New Drug (IND) application for the candidate has been submitted in the U.S. for treatment of patients with certain hematologic cancers.
Meanwhile, the company continues to progress with its pipeline. Currently, the company’s lead candidate, C-Cure, is in the follow-up period of its phase III (CHART-1) study for heart failure indications. Data readout is expected in mid-2016. The CHART-2 study is expected to be initiated before year end.
We remind investors that in early November, Celyad announced the initiation of a certification procedure by the European Medicines Agency (EMA) for non-clinical data on C-Cure.
We note that the MM market is presently crowded with drugs like Kyprolis, Velcade and Darzalex among others. On the other hand, a drug approved for the treatment of AML is Pfizer Inc.’s PFE Idamycin.
Celyad currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the health care sector include Achillion Pharmaceuticals, Inc. ACHN and Corcept Therapeutics Incorporated CORT, both sporting a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment